This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

David L. Macdonald Appointed CEO Of GeneLink BioSciences, Inc.

ORLANDO, Fla., Dec. 28 /PRNewswire-FirstCall/ -- GeneLink BioSciences, Inc., (OTC Bulletin Board: GNLK) a leading consumer genomics and biotechnology company ( www.genelinkbio.com), is pleased to announce the appointment of David L. Macdonald as its interim Chief Executive Officer, effective December 28, 2009.  

Mr. Macdonald is a proven entrepreneurial leader with more than 25 years of experience building high performance teams and achieving aggressive goals in technical product and service environments.  He will be applying his skills, which are reflected by an impressive track record in the successful commercialization of proprietary healthcare related technology, international expansion, operational excellence, regulatory compliance, product development and execution of licensing opportunities.  Mr. Macdonald will help GeneLink develop and execute its plan to exploit its position as a scientific leader in consumer genomics.  

Prior to joining GeneLink, Mr. Macdonald served as the President and Chief Operating Officer at Nichols Institute Diagnostics (NID).  Upon acquisition of NID by Corning Life Sciences and the eventual spinout of Quest Diagnostics, Mr. Macdonald became a Vice President at Quest where, along with having responsibility for NID, he was a senior team member of Quest – a $5 billion laboratory services business with 30,000 employees.  He also served as CEO and Director at AltheaDx, CEO, President and Director at Nanomix, Senior Vice President of Global Operations and Business Development at Nanogen, and as CEO, President and a member of the Board of Directors at Progeny Systems.

Monte E. Taylor, Jr., who has served as the CEO of both GeneLink and its wholly owned subsidiary GeneWize, will continue as the CEO of GeneWize.  Bernard L. Kasten, MD, GeneLink's Executive Chairman reflected, "We wish to acknowledge that the success that GeneWize has enjoyed is largely due to the tireless efforts of Monte Taylor.  By developing an enhanced infrastructure at GeneLink to support GeneWize, Mr. Taylor will be able to focus his efforts toward growing GeneWize.  GeneLink, led by Mr. Macdonald, is committed to supporting Mr. Taylor, his GeneWize management team, our marketing affiliates and our customers."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
GNLK $0.00 0.00%
AAPL $130.28 0.00%
FB $79.19 0.00%
GOOG $532.11 0.00%
TSLA $250.80 0.00%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs